Cargando…
Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
Acute pancreatitis is the most common gastrointestinal pathology that warrants hospital admission, with an estimated incidence of 13-45/100,000 annually in the US. The overall mortality is low but is significantly increased in 15-25% of patients that develop severe disease, likely secondary to an in...
Autores principales: | Berger, Amnon A, Sherburne, Robert, Urits, Ivan, Patel, Haresh, Eskander, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748593/ https://www.ncbi.nlm.nih.gov/pubmed/33365220 http://dx.doi.org/10.7759/cureus.11551 |
Ejemplares similares
-
Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
por: Berger, Amnon A, et al.
Publicado: (2020) -
Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment
por: Suh, Winston, et al.
Publicado: (2020) -
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
por: Budoff, Matthew, et al.
Publicado: (2018) -
Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014) -
Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)